The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Dexloxiglumida     (4R)-4-[(3,4-dichlorophenyl) carbonylamino]...

Synonyms: Dexloxiglumide, PubChem16049, CHEMBL550781, SureCN366142, CR-2017, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Dexloxiglumide

 

High impact information on Dexloxiglumide

 

Biological context of Dexloxiglumide

 

Anatomical context of Dexloxiglumide

 

Associations of Dexloxiglumide with other chemical compounds

 

Gene context of Dexloxiglumide

 

Analytical, diagnostic and therapeutic context of Dexloxiglumide

  • AIMS: To evaluate the effects of dexloxiglumide, a CCK-1 receptor antagonist, on gastrointestinal transit (GIT) and symptoms in patients with constipation-predominant IBS (C-IBS); and to explore the influence of CCK-1 receptor polymorphisms on gut transit and the pharmacodynamic response to therapy [5].
  • Dexloxiglumide plasma and urinary concentration, determined using validated HPLC methods with UV detection, were used for the pharmacokinetic analysis by standard noncompartmental methods [17].
  • SUBJECTS AND METHODS: Twelve volunteers were enrolled in the present study and received orally 100, 200 and 400 mg of dexloxiglumide as tablets as a single dose followed by repeated t.i.d. doses for 7 days according to a randomized, double-blind, double-dummy complete crossover design [17].
  • However, by April 2002 its development for indications other than acute and chronic pancreatitis had been discontinued in favor of the D-enantiomer, dexloxiglumide [449509], which is in clinical trials for gastrointestinal disorders [370620] [18].

References

  1. The role of fat and cholecystokinin in functional dyspepsia. Fried, M., Feinle, C. Gut (2002) [Pubmed]
  2. Pharmacokinetic profile of dexloxiglumide. Persiani, S., D'Amato, M., Jakate, A., Roy, P., Wangsa, J., Kapil, R., Rovati, L.C. Clinical pharmacokinetics (2006) [Pubmed]
  3. Different actions of CCK on pancreatic and gastric growth in the rat: effect of CCK(A) receptor blockade. Varga, G., Kisfalvi, K., Pelosini, I., D'Amato, M., Scarpignato, C. Br. J. Pharmacol. (1998) [Pubmed]
  4. Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide. Jakate, A.S., Roy, P., Patel, A., Abramowitz, W., Persiani, S., Wangsa, J., Kapil, R. British journal of clinical pharmacology. (2005) [Pubmed]
  5. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Cremonini, F., Camilleri, M., McKinzie, S., Carlson, P., Camilleri, C.E., Burton, D., Thomforde, G., Urrutia, R., Zinsmeister, A.R. Am. J. Gastroenterol. (2005) [Pubmed]
  6. Characterization of dexloxiglumide in vitro biopharmaceutical properties and active transport. Tolle-Sander, S., Grill, A., Joshi, H., Kapil, R., Persiani, S., Polli, J.E. Journal of pharmaceutical sciences. (2003) [Pubmed]
  7. Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Webber, C., Roth, A., Persiani, S., Peard, A.J., Makovec, F., Kapil, R.P., John, B.A., Holding, J.D., D'amato, M., Cybulski, Z.R., Chasseaud, L.F., Rovati, L.C. Xenobiotica (2003) [Pubmed]
  8. Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the rat. Webber, C., Stokes, C.A., Persiani, S., Makovec, F., McBurney, A., Kapil, R.P., John, B.A., Houchen, T.L., D'Amato, M., Chasseaud, L.F. European journal of drug metabolism and pharmacokinetics. (2003) [Pubmed]
  9. CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications. Maselli, M.A., Mennuni, L. Minerva gastroenterologica e dietologica. (2003) [Pubmed]
  10. Effect of three nonpeptide cholecystokinin antagonists on human isolated gallbladder. Maselli, M.A., Piepoli, A.L., Pezzolla, F., Guerra, V., Caruso, M.L., Mennuni, L., Lorusso, D., Makovec, F. Dig. Dis. Sci. (2001) [Pubmed]
  11. Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat. Varga, G., Kisfalvi, K., D'Amato, M., Scarpignato, C. J. Physiol. Paris (1997) [Pubmed]
  12. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Scarpignato, C., Kisfalvi, I., D'Amato, M., Varga, G. Aliment. Pharmacol. Ther. (1996) [Pubmed]
  13. Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women. Roy, P., Jakate, A.S., Patel, A., Abramowitz, W., Wangsa, J., Persiani, S., Kapil, R. Journal of clinical pharmacology. (2005) [Pubmed]
  14. Basic and clinical pharmacology of new motility promoting agents. Galligan, J.J., Vanner, S. Neurogastroenterol. Motil. (2005) [Pubmed]
  15. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Scarpignato, C., Pelosini, I. Can. J. Gastroenterol. (1999) [Pubmed]
  16. Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450. Hall, M., Persiani, S., Cheung, Y.L., Matthews, A., Cybulski, Z.R., Holding, J.D., Kapil, R., D'Amato, M., Makovec, F., Rovati, L.C. Biopharmaceutics & drug disposition. (2004) [Pubmed]
  17. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males. Persiani, S., D'Amato, M., Makovec, F., Tavares, I.A., Bishai, P.M., Rovati, L.C. International journal of clinical pharmacology and therapeutics. (2002) [Pubmed]
  18. Loxiglumide Rotta research. Katschinski, M. IDrugs : the investigational drugs journal. (2002) [Pubmed]
 
WikiGenes - Universities